Digestive Diseases Research Center, Digestive Diseases Research Institute, Shariati Hospital Tehran University of Medical Sciences, Tehran, Iran.
Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
BMC Gastroenterol. 2022 Mar 10;22(1):119. doi: 10.1186/s12876-022-02190-4.
We aimed to find the association between gastrointestinal (GI) and respiratory symptoms with mortality and hospitalization among COVID-19 patients.
We analyzed the registered data of COVID-19 patients from February 20, 2020, to March 10, 2021. Depending on the patients' disease symptoms, four categories were defined: patients with only GI symptoms, patients with only respiratory symptoms, patients with both symptoms, and patients with other symptoms. Logistic regression analysis was used to assess the association of groups with outcomes.
A total of 42,964 patients from 23 hospitals were included, of which 26.5% patients had at least one or more GI symptoms. Of total patients, 51.58% patients were hospitalized among which 22.8% had at least one or more GI symptoms. GI symptoms significantly decreased the odds of mortality (OR 0.72, 95% CI 0.56-0.92), but respiratory symptoms increased the odds for mortality (1.36: 1.24-1.50), compared with patients with other symptoms. Moreover, the odds ratio of patients who had both respiratory and GI symptoms increased (1.52: 1.31-1.78) compared with patients with other symptoms. The same results were observed for hospitalization as the outcome.
Our study showed that the presence of GI symptoms in COVID-19 at the time of admission was associated with a lower odds of hospitalization and mortality; however, this association had higher odds for respiratory symptoms.
我们旨在探讨 COVID-19 患者胃肠道(GI)和呼吸道症状与死亡率和住院率之间的关系。
我们分析了 2020 年 2 月 20 日至 2021 年 3 月 10 日期间 COVID-19 患者的登记数据。根据患者的疾病症状,将其分为以下四类:仅有 GI 症状的患者、仅有呼吸道症状的患者、同时有两种症状的患者和有其他症状的患者。采用 logistic 回归分析评估各组与结局的关系。
共纳入了来自 23 家医院的 42964 名患者,其中 26.5%的患者至少有一种或多种 GI 症状。在所有患者中,51.58%的患者住院,其中 22.8%的患者至少有一种或多种 GI 症状。与其他症状患者相比,GI 症状显著降低了死亡率的可能性(OR 0.72,95%CI 0.56-0.92),而呼吸道症状则增加了死亡率的可能性(1.36:1.24-1.50)。此外,与其他症状患者相比,同时有呼吸道和 GI 症状的患者的比值比增加(1.52:1.31-1.78)。将住院作为结局,也得到了相同的结果。
本研究表明,COVID-19 患者入院时出现 GI 症状与较低的住院和死亡率几率相关;然而,这种关联对于呼吸道症状的几率更高。